Clincosm LogoSign in Get a demo

nsclc stage iiib

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC Trial in China (Cadonilimab, Anlotinib, Docetaxel)

Recruiting
  • NSCLC Stage IV
  • +2 more
  • Hefei, Anhui, China
  • +4 more
Apr 15, 2023

NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)

Active, not recruiting
  • NSCLC Stage IIIB
  • +4 more
  • Hong Kong, Hong Kong
  • +8 more
Jan 10, 2023

NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Dec 7, 2022

NSCLC Stage IIIB, NSCLC Stage IV Trial in Frankfurt (Osimertinib, Pemetrexed, Cisplatin)

Recruiting
  • NSCLC Stage IIIB
  • NSCLC Stage IV
  • Berlin, Germany
  • +8 more
Oct 25, 2022

HCC, NSCLC Stage IIIB, NSCLC Stage IV Trial in Worldwide (YH001 + Toripalimab)

Not yet recruiting
  • HCC
  • +2 more
  • YH001 + Toripalimab
  • Canton, Ohio, Armenia
  • +21 more
Jul 20, 2022

NSCLC Stage IV, NSCLC Stage IIIB Trial in United States (Ipatasertib)

Recruiting
  • NSCLC Stage IV
  • NSCLC Stage IIIB
  • Fairway, Kansas
  • +4 more
Nov 29, 2021

Ensatinib in alK-positive Patients Undergoing Initial Treatment

Recruiting
  • ALK Positive
  • +2 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 16, 2021

NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC Trial in Canada, Hong Kong, United States (tarloxotinib bromide)

Terminated
  • NSCLC, Stage IV
  • +7 more
  • tarloxotinib bromide
  • Irvine, California
  • +13 more
Nov 11, 2021

NSCLC Stage IIIB, NSCLC Stage IV Trial in Shanghai (SPH1188-11)

Withdrawn
  • NSCLC Stage IIIB
  • NSCLC Stage IV
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 31, 2021

Genomic and Transcriptomic Patterns Between CTC and Metastatic

Active, not recruiting
  • NSCLC Stage IV
  • NSCLC Stage IIIB
  • cohort study
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 18, 2021

NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

Recruiting
  • NSCLC Stage IIIB
  • +4 more
  • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
  • Carboplatin + Pemetrexed + Atezolizumab
  • Angers, France
  • +30 more
Jun 7, 2021

NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB Trial in Heidelberg (Atezolizumab)

Recruiting
  • NSCLC Stage II
  • +2 more
  • Heidelberg, BaWü, Germany
    Thoraxklinik Heidelberg gGmbH
Apr 25, 2021

Followed by 3rd Generation EGFR-TKI in EGFR Mutation Positive

Recruiting
  • EGFR Activating Mutation
  • +3 more
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 23, 2021

Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Tampa (dietary supplement, radiation, drug, other)

Withdrawn
  • Non Small Cell Lung Cancer
  • +6 more
  • Impact® Advanced Recovery
  • +6 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Sep 9, 2020

NSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation Trial in Hong Kong (Atezolizumab, Bevacizumab, Carboplatin)

Unknown status
  • NSCLC Stage IIIB
  • +2 more
  • Hong Kong, Hong Kong
    Department of Clinical Oncology
Apr 16, 2019

NSCLC Stage IV, NSCLC Stage IIIB Trial (Intervention/treatment)

Unknown status
  • NSCLC Stage IV
  • NSCLC Stage IIIB
  • Intervention/treatment
  • (no location specified)
Jul 11, 2018

NSCLC Stage IIIB, NSCLC Stage IV, Hepatocellular Carcinoma by BCLC Stage Trial (Immune Killer Cells (IKC))

Completed
  • NSCLC Stage IIIB
  • +4 more
  • Immune Killer Cells (IKC)
  • (no location specified)
May 3, 2018

NSCLC Stage IIIB, Concomitant Radiochemotherapy Trial in Saint-Etienne (Paclitaxel, vinorelbine, cisplatin)

Completed
  • NSCLC Stage IIIB
  • Concomitant Radiochemotherapy
  • Paclitaxel, vinorelbine, cisplatin
  • Saint-Etienne, France
    CHU Saint-Etienne Pneumologie
Mar 9, 2016